CA2853484C - Cysteamine in the treatment of fibrotic disease - Google Patents

Cysteamine in the treatment of fibrotic disease Download PDF

Info

Publication number
CA2853484C
CA2853484C CA2853484A CA2853484A CA2853484C CA 2853484 C CA2853484 C CA 2853484C CA 2853484 A CA2853484 A CA 2853484A CA 2853484 A CA2853484 A CA 2853484A CA 2853484 C CA2853484 C CA 2853484C
Authority
CA
Canada
Prior art keywords
cysteamine
fibrosis
interstitial
salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2853484A
Other languages
English (en)
French (fr)
Other versions
CA2853484A1 (en
Inventor
Allison A. Eddy
Daryl M. Okamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of CA2853484A1 publication Critical patent/CA2853484A1/en
Application granted granted Critical
Publication of CA2853484C publication Critical patent/CA2853484C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2853484A 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease Active CA2853484C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (2)

Publication Number Publication Date
CA2853484A1 CA2853484A1 (en) 2013-05-02
CA2853484C true CA2853484C (en) 2018-08-21

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2853484A Active CA2853484C (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Country Status (7)

Country Link
US (2) US9468612B2 (https=)
AU (1) AU2011379972B2 (https=)
BR (1) BR112014009789A2 (https=)
CA (1) CA2853484C (https=)
IN (1) IN2014DN03049A (https=)
MX (1) MX2014004994A (https=)
WO (1) WO2013062544A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316877B1 (en) * 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
CA3017797A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
WO2018148254A1 (en) * 2017-02-07 2018-08-16 Children's Hospital Medical Center Treatment of asthma with cysteamine
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
US10828372B2 (en) 2017-11-10 2020-11-10 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
WO2020079186A1 (en) 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
WO2020210218A1 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Methods for treating inherited eye defects
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
JP2887325B2 (ja) 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
FI921353A0 (fi) 1989-09-29 1992-03-27 Jolla Cancer Res Found Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.
EP0502036B1 (en) 1989-11-22 1995-12-20 Genentech, Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
WO1993009800A1 (en) 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
WO1994010187A1 (en) 1992-10-30 1994-05-11 Hsc Research And Development Limited Partnership COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
AU2404695A (en) 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
AU740052B2 (en) 1996-10-25 2001-10-25 Ethicon Inc. Anti-fibrotic agent assay
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1506191A1 (en) 2002-05-15 2005-02-16 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
EP1575506A4 (en) 2002-07-25 2008-04-23 Scios Inc METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US20060079680A1 (en) 2002-11-22 2006-04-13 Eli Lilly And Company Patent Division Pyrazoloazepine compounds as pharmaceutical agents
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004048930A2 (en) 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
WO2004050659A1 (en) 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
MXPA06008157A (es) 2003-12-24 2007-09-07 Johnson & Johnson Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
AU2005280168A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as TGF-beta inhibitors
AU2005280167A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
EP1812450A2 (en) 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
HRP20130590T1 (en) * 2007-11-30 2013-08-31 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Also Published As

Publication number Publication date
AU2011379972A1 (en) 2014-05-15
AU2011379972B2 (en) 2016-05-12
US20140275279A1 (en) 2014-09-18
CA2853484A1 (en) 2013-05-02
US20170165207A1 (en) 2017-06-15
US9925154B2 (en) 2018-03-27
MX2014004994A (es) 2014-08-27
IN2014DN03049A (https=) 2015-05-15
WO2013062544A1 (en) 2013-05-02
US9468612B2 (en) 2016-10-18
BR112014009789A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
CA2853484C (en) Cysteamine in the treatment of fibrotic disease
Ermer et al. Oxalate homeostasis
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
AU2015218642A1 (en) Compositions of pentosan polysulfate salts for oral administration and methods of use
CN110430876A (zh) 用于组合疗法的药物组合物
RS59816B1 (sr) Nova primena
JP6507336B2 (ja) Ｃｂｐ／カテニン阻害剤を用いる肝線維症の治療
TW201332547A (zh) 用於預防或治療貓之全身性疾病之血管緊張素ｉｉ受體拮抗劑
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
Aboolian et al. Diabetic kidney disease: from pathogenesis to novel treatment possibilities
ES2374399T3 (es) Piridoxamina para uso en el tratamiento de nefropatía diabética en diabetes tipo ii.
CN114096257A (zh) 包含如sglt 1/2抑制剂的sglt抑制剂的治疗
JPWO2018193648A1 (ja) アルカリ性化剤による血液浄化
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
JP2010533650A (ja) 代謝性障害の治療のための組成物
WO2008042773A2 (en) Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
Nakhoul et al. Diabetic nephropathy from RAAS to autophagy: the era for new players
US20050059660A1 (en) Novel combination
AU2018330416B2 (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver
JP2022533603A (ja) １５－ＨＥＰＥおよび／または１５－ＨＥＴｒＥを含む組成物、ならびに心血管代謝性疾患、メタボリックシンドローム、および／または関連疾患を治療または予防する方法
EP4566598A1 (en) Compositions providing sglt2i and bhb activity and methods of use to treat human disease
ES2398477T3 (es) Agente para la prevención y/o el tratamiento de glomerulopatía
KR20190141774A (ko) 이상지질혈증의 치료를 위한 니코틴아미드
Zhao The physiological role of Nrf2 in diabetic kidney disease
JP2019504870A (ja) 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140522

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250428